The biotechnology company will tap into Catalent’s expertise in induced pluripotent stem cells and advanced cell-therapy manufacturing
The move comes as the global biotech and biopharma CDMO market continues to surge, fueled by rising demand
The new entity will operate with separate resources, funding, and operations, while BioNTech will contribute related rights and mRNA technologies to support its ambitious mission
The trial’s primary goal is to evaluate vipoglanstat’s effect on endometriosis-related pain during non-menstrual days
The protections extend through at least 2035, with the potential for further extensions
The new facilities are designed to provide focused, patient-centric care through advanced diagnostics, minimally invasive treatments, and multidisciplinary expertise
The agreement brings to market a method pioneered at CU Boulder that enables the reliable synthesis of long RNA strands
Subscribe To Our Newsletter & Stay Updated